Skip to: Content
Skip to: Site Navigation
Skip to: Search
SUNDAY, NOVEMBER 22, 2009
| Subscribe to Newser's RSS feeds RSS | Follow Newser on Twitter Twitter

NEWS ABOUT: Genentech

Genentech stories: 11 news summaries
Puppetmasters

Big Pharma Lobbyists Put Words Into Reps' Mouths

We 'didn't know' where the language came from, reps plead

Nov 15, 09 8:37 AM CST
(Newser) - Yep, that's an echo you hear in the House chamber. The New York Times has obtained emails showing that language drafted by lobbyists working for biotech giant Genentech made it almost unchanged into statements and speeches made on health care—by Democrats and Republicans alike. A Genentech lawyer told staffers,... More »

MORE ABOUT:
health care • lobbying • Genentech • lobbying blitz • House Democrats • pharmaceutical industry • House Republicans

Colon Cancer Drug Flunks Important Test

Avastin's effects on early-stage disease don't meet expectations

Apr 22, 09 8:07 AM CDT
(Newser) - Clinical trials to determine the drug Avastin’s effects on early-stage colon cancer were a big disappointment for drug firm Genentech, the New York Times reports. The drug, which is typically used in late-stage cancer, didn’t significantly cut the recurrence rate among 2,700 subjects in the early stages,... More »

MORE ABOUT:
study • drug companies • cancer research • cancer treatment • Genentech • Roche • Avastin • clinical trials

(Newser) - Swiss drug giant Roche has succeeded in its quest to own biotech firm Genentech outright, and will purchase the 44% of shares it does not already own for $95 each, the San Francisco Chronicle reports today. The $46.8 billion deal comes after months of haggling, wherein Roche offered as... More »

MORE ABOUT:
California • San Francisco • pharmaceutical companies • hostile takeover • mergers and acquisitions • biotechnology • Genentech • Roche • biotech companies

 Colon Cancer Gene Discovered 

Cancer growth gene identified

Sep 15, 08 6:00 AM CDT
(Newser) - Researchers have discovered a key gene that may contribute to the growth of colon cancer and could provide a target for new therapies, Bloomberg reports. The gene, CDK8, controls a cell growth switch that researchers think might spur the development of many tumors. The discovery may help up to 50%... More »

MORE ABOUT:
medical research • cancer research • colon cancer • Genentech • Harvard • Dana Farber Cancer Institute • AstraZeneca • Tufts Center for the Study of Drug Development

Roche Makes Genentech Takeover Bid

Swiss pharma bids $43.7B for remaining shares of biotech firm

Jul 21, 08 6:55 AM CDT
(Newser) - Swiss pharmaceutical company Roche today offered $43.7 billion for the outstanding shares of Genentech, the San Francisco-based biotech firm in which Roche already owns a 55.9% stake, the Wall Street Journal reports. The $89-a-share offer is the latest in a series of big pharma companies, whose new drug... More »

MORE ABOUT:
mergers and acquisitions • takeover • Genentech • Roche Holding • Pharamceuticals

Cancer Drug Sales Push Genentech Profits Up 12%

But analysts say Avastin sales slowing

Apr 11, 08 8:28 AM CDT
(Newser) - Biotech firm Genentech said sales of its blockbuster cancer drug Avastin fueled a first-quarter profit increase of 12%, reports the Wall Street Journal, but the $600 million in sales was below analysts’ projected $622 million, causing some to grumble the drug may have reached a sales plateau. Genentech stock... More »

MORE ABOUT:
FDA • breast cancer • corporate earnings • Genentech • Roche Holding • Avastin

FDA Clears Avastin for Breast Cancer

Ruling rejects own panel's advice;
drug now used for lung, colon treatment

Feb 22, 08 6:06 PM CST
(Newser) - The FDA has approved a drug currently prescribed to treat lung and colon cancer for use on breast cancer patients, the AP reports. The decision defies the advice of the FDA's own advisory panel, which recommended that Avastin not be used to treat breast cancer on the grounds that it... More »

MORE ABOUT:
FDA • breast cancer • lung cancer • colon cancer • Genentech • mortality • tumors • Avastin

Fortune Names Top Employers

Fortune Lists the top 100

Feb 3, 08 5:32 AM CST
(Newser) - Thinking of a career move? Fortune Magazine has released its 100 best employers for 2008 list—and the top 10 are:
  1. Google (Mountain View, CA)
  2. Quicken Loans (Livonia, MI)
  3. Wegmans Food Markets (Rochester, NY)
  4. Edward Jones (St. Louis, MO)
  5. Genentech (South San Francisco, CA)
More »

MORE ABOUT:
Google • Starbucks • list • Cisco • Genentech • Fortune • best companies • Wegmans • Quicken • Edward Jones

Street Yawns at Genentech Quarterlies

Despite beating analysts' revenue and profit forecast, biotech's share price drops

Jan 15, 08 11:09 AM CST
(Newser) - Drug maker Genentech – struggling with near-flat sales of its two premier drugs, Avastin and Rituxan – managed to outperform analyst’s fourth quarter expectations – barely, reports the Associated Press. The one-time biotech uber star, which recorded phenomenal growth in each of the two previous years, showed only a... More »

MORE ABOUT:
earnings reports • biotechnology • Genentech • pharmaceutical • Avastin • Rituxan

FDA Panel Rejects Breast Cancer Drug

Uncertainties on risk sink bid to expand
uses for Avastin

Dec 5, 07 4:34 PM CST
(Newser) - An FDA panel rejected a drug to treat advanced breast cancer by 5-to-4 vote, the Wall Street Journal reports. The drug Avastin is already used to treat colon and lung cancer, but the panel said it did not have sufficient data to weigh the risks and benefits of using the... More »

MORE ABOUT:
FDA • breast cancer • Genentech • Avastin

Biotech Giant Slashes Jobs

World biggest biotech cuts 2,600 jobs in $2B restructuring

Aug 16, 07 1:34 AM CDT
(Newser) - Biotech giant Amgen is slashing spending by $1.9 billion by cutting up to 14 percent of its workforce— 2,600 jobs—and closing some production facilities. The restructuring was triggered by plummeting sales of the company's anemia drug Aranesp. The shake up demonstrates that biotech operations are not immune... More »

MORE ABOUT:
biotechnology • Amgen • Aranesp • Genentech • restructuring • Cera • Roche Holding • Kevin Sharer

11 Stories


from our news partners